A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer

Kenzo Soejima, Katsuhiko Naoki, Kota Ishioka, Morio Nakamura, Michie Nakatani, Ichiro Kawada, Hideo Watanabe, Ichiro Nakachi, Hiroyuki Yasuda, Ryosuke Satomi, Sohei Nakayama, Satoshi Yoda, Sinnosuke Ikemura, Hideki Terai, Takashi Sato, Keiko Ohgino, Daisuke Arai, Tetsuo Tani, Aoi Kuroda, Makoto NishinoTomoko Betsuyaku

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Purpose: The number of elderly patients with advanced non-small cell lung cancer (NSCLC) is increasing. Although several studies have suggested the benefit of chemotherapy with a platinum doublet for elderly patients with advanced NSCLC, this treatment is still controversial in this age group. To evaluate the efficacy and tolerability of combination chemotherapy with biweekly paclitaxel and carboplatin for elderly patients with advanced NSCLC, we conducted a multicenter, non-randomized, open label, phase II trial. Methods: We recruited patients aged ≥70 years with clinical stage IIIB and IV NSCLC and ECOG performance status (PS) of 0-2. Patients received paclitaxel (90 mg/m2) and carboplatin (AUC = 2.5) on day 1 and 15, every 4 weeks. The primary endpoint was overall response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety. Results: Sixty-five patients (median age 79 years; range 70-87 years) were enrolled. Forty-nine patients were men, and 48 were stage IV. The PS was 0, 1, and 2 in 28, 33, and 4 patients, respectively. The histological type of NSCLC was non-squamous in 69.3 % and squamous cell carcinoma in 30.7 % of patients. The median number of treatment cycles was 3 (range 1-6). The response rate was 29.4 % (95 % CI 18.7-43.0), and the disease control rate was 78.0 % (95 % CI 64.8-87.2). Median PFS and OS were 3.8 months (95 % CI 1.9-5.3) and 17.3 months (95 % CI 10.4-25.1), respectively. The most common grade 3 or 4 toxicities were neutropenia (27 %), leukopenia (15 %), infection (10 %), and anemia (8 %). Conclusion: The combination of biweekly paclitaxel and carboplatin was effective and well tolerated in elderly patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)513-519
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume75
Issue number3
DOIs
Publication statusPublished - 2015 Mar

Keywords

  • Carboplatin
  • Elderly
  • Non-small cell lung cancer
  • Paclitaxel
  • Phase II trial

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this